MedTrace Logo

Alpha-1-Antitrypsin-Deficiency in COVID-19

NCT04799873 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-05-25

No results posted yet for this study

Summary

The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored.

Conditions

  • Covid19

Interventions

DRUG

AAT( Alpha 1 Antitrypsin)

AAT administration based on clinical indication

Sponsors & Collaborators

  • Universität des Saarlandes

    lead OTHER

Principal Investigators

  • Robert Bals · UDS

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-08
Primary Completion
2020-12-01
Completion
2020-12-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04799873 on ClinicalTrials.gov